Document Detail

Remission of seizures in a population-based adult cohort with a newly diagnosed unprovoked epileptic seizure.
MedLine Citation:
PMID:  11554889     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To investigate the probability of achieving remission of seizures after a newly diagnosed unprovoked epileptic seizure in an adult population-based cohort. METHODS: 107 patients aged 17 years or older with a newly diagnosed unprovoked epileptic seizure (index seizure) in 1985 through 1987 were followed up until the date of death or to the end of 1996. The proportion of cases during follow-up that attained a 1-year, 3-year, 5-year remission was calculated by actuarial analyses. Variables for stratification were age at diagnosis, seizure type, etiology, EEG, and the occurrence of seizures within 1 year of initiation of antiepileptic drug (AED) therapy. RESULTS: Cumulative 1-, 3- and 5-year remission rates were 68, 64, and 58%. There was no statistically significant difference regarding time points of achieving a 1-year remission after epilepsy diagnosis and the subsequent probability during follow-up of attaining a 5-year remission. Having seizures within 1 year after beginning with an AED was a statistically significant predictor of never achieving 1-year remission of seizures during follow-up (refractory seizures). Other stratified variables were not statistically significant predictors. CONCLUSIONS: Seizure prognosis for the majority of patients with newly diagnosed epilepsy is good. The time required after epilepsy diagnosis to achieve a 1-year remission of seizures does not affect the probability of additionally achieving a 5-year remission. Patients with refractory seizures can be identified within a few years from diagnosis of epilepsy. These patients must be targeted early for optimization of pharmacologic treatment, possible surgery, and psychosocial intervention.
H Lindsten; H Stenlund; L Forsgren
Related Documents :
12397139 - Long term outcome of temporal lobe epilepsy surgery: analyses of 140 consecutive patients.
17369059 - Efficacy and safety of levetiracetam as adjunctive treatment of refractory partial seiz...
9596199 - Psychiatric outcome of temporal lobectomy for epilepsy: incidence and treatment of psyc...
15894459 - Failed surgery for temporal lobe epilepsy: predictors of long-term seizure-free course.
16178009 - Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrosp...
12649109 - Multicentre phase ii study and pharmacokinetic analysis of irinotecan in chemotherapy-n...
16051519 - Short- and long-term results of a programme for the prevention of readmissions and mort...
14524579 - Neither folic nor folinic acid normalize homocysteine levels in hemodialysis patients.
24478949 - Comparative evaluation of ultraviolet and microwave sanitization techniques for toothbr...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Epilepsia     Volume:  42     ISSN:  0013-9580     ISO Abbreviation:  Epilepsia     Publication Date:  2001 Aug 
Date Detail:
Created Date:  2001-09-13     Completed Date:  2001-12-04     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  2983306R     Medline TA:  Epilepsia     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1025-30     Citation Subset:  IM    
Department of Neurology, Umeå University Hospital, Umeå, Sweden.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Actuarial Analysis
Age Factors
Anticonvulsants / therapeutic use
Cohort Studies
Electroencephalography / statistics & numerical data
Epilepsy / diagnosis*,  physiopathology,  therapy
Follow-Up Studies
Middle Aged
Patient Care Planning
Risk Factors
Treatment Outcome
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Comparison of hippocampal volumetry at 1.5 tesla and at 3 tesla.
Next Document:  Time trends in incidence, mortality, and case-fatality after first episode of status epilepticus.